Prices updated 23 June 2026, 9:40 am AEST · Data: Financial Modeling Prep
Market Cap
$54.06B
Volume
2.2M
P/E Ratio
34.11
EPS
$0.8445
Dividend Yield
1.44%
52-Week High
$275.79
52-Week Low
$90.00
Beta
0.094
CSL (ASX: CSL) is an Australian-listed company in the Healthcare sector with a market capitalisation of $54.06B and the 21st-largest security on the ASX by market capitalisation. The CSL share price is $112.88, down 2.96% today and down 52.76% over the past 12 months. Shares have traded between $90.00 and $275.79 over the past 52 weeks. CSL trades on a price-to-earnings ratio of 34.11, above the Healthcare sector median of 14.96, and pays a trailing dividend yield of 1.44%. In its most recent reported period (ending 31 Dec 2025), CSL reported revenue of $8.44B and a net profit of $408.4M (4.8% margin).
Charts
$111.95
24H Range
$110.89
$116.29
52-Week Range
$90.00
$275.79
About CSL Limited
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
CSL is held by 10 ASX-listed funds tracked on this site. The largest allocation is in Vanguard MSCI Australian Large Companies Index ETF (ASX: VLC) at 5.98% of its portfolio.
